Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT02430480
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 16
- Registration Number
- NCT02429193
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02407054
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT02384382
- Locations
- 🇺🇸
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Wimr Pet/Ct, Madison, Wisconsin, United States
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02380313
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 42
- Registration Number
- NCT02366494
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Duke University
- Target Recruit Count
- 38
- Registration Number
- NCT02353715
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Taro Iguchi, MD, PHD
- Target Recruit Count
- 104
- Registration Number
- NCT02346578
- Locations
- 🇯🇵
Osaka City University Graduate School of Medicine, Osaka, Japan
Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 24
- Registration Number
- NCT02339168
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1068
- Registration Number
- NCT02319837
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹AKH - Medizinische Universität Wien, Vienna, Austria
🇨🇦Vancouver Prostate Centre, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.